FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2037648619> ?p ?o ?g. }

• W2037648619 endingPage "1046" @default.
• W2037648619 startingPage "1040" @default.
• W2037648619 abstract "Background & AimsWe conducted an open-label phase 2 study to assess the efficacy and safety of the oral nucleotide polymerase inhibitor sofosbuvir in combination with ribavirin in patients of Egyptian ancestry, chronically infected with genotype 4 hepatitis C virus (HCV).MethodsTreatment-naive and previously treated patients with genotype 4 HCV were randomly allocated in a 1:1 ratio to receive sofosbuvir 400 mg and weight-based ribavirin, for 12 or 24 weeks. The primary efficacy endpoint was the proportion of patients with sustained virologic response (HCV RNA <25 IU/ml) 12 weeks after cessation of therapy (SVR12).ResultsThirty treatment-naive and thirty previously treated patients were enrolled and treated for 12 weeks (n = 31) or 24 weeks (n = 29). Overall, 23% of patients had cirrhosis and 38% had diabetes. 14% of treatment-naive patients were interferon ineligible and 63% of treatment-experienced patients had prior non-response. SVR12 was achieved by 68% of patients (95% CI, 49–83%) in the 12-week group, and by 93% of patients (95% CI, 77–99%) in the 24-week group. The most common adverse events were headache, insomnia, and fatigue. No patient discontinued treatment due to an adverse event.ConclusionsThe findings from the present study suggest that 24 weeks of sofosbuvir plus ribavirin is an efficacious and well tolerated treatment in patients with HCV genotype 4 infection. We conducted an open-label phase 2 study to assess the efficacy and safety of the oral nucleotide polymerase inhibitor sofosbuvir in combination with ribavirin in patients of Egyptian ancestry, chronically infected with genotype 4 hepatitis C virus (HCV). Treatment-naive and previously treated patients with genotype 4 HCV were randomly allocated in a 1:1 ratio to receive sofosbuvir 400 mg and weight-based ribavirin, for 12 or 24 weeks. The primary efficacy endpoint was the proportion of patients with sustained virologic response (HCV RNA <25 IU/ml) 12 weeks after cessation of therapy (SVR12). Thirty treatment-naive and thirty previously treated patients were enrolled and treated for 12 weeks (n = 31) or 24 weeks (n = 29). Overall, 23% of patients had cirrhosis and 38% had diabetes. 14% of treatment-naive patients were interferon ineligible and 63% of treatment-experienced patients had prior non-response. SVR12 was achieved by 68% of patients (95% CI, 49–83%) in the 12-week group, and by 93% of patients (95% CI, 77–99%) in the 24-week group. The most common adverse events were headache, insomnia, and fatigue. No patient discontinued treatment due to an adverse event. The findings from the present study suggest that 24 weeks of sofosbuvir plus ribavirin is an efficacious and well tolerated treatment in patients with HCV genotype 4 infection." @default.
• W2037648619 created "2016-06-24" @default.
• W2037648619 creator A5003723462 @default.
• W2037648619 creator A5007464229 @default.
• W2037648619 creator A5008132779 @default.
• W2037648619 creator A5010739819 @default.
• W2037648619 creator A5019109535 @default.
• W2037648619 creator A5020337780 @default.
• W2037648619 creator A5022259822 @default.
• W2037648619 creator A5023275678 @default.
• W2037648619 creator A5035044684 @default.
• W2037648619 creator A5039624341 @default.
• W2037648619 creator A5046920680 @default.
• W2037648619 creator A5055304656 @default.
• W2037648619 creator A5057491763 @default.
• W2037648619 creator A5064179616 @default.
• W2037648619 creator A5072939769 @default.
• W2037648619 creator A5089993955 @default.
• W2037648619 date "2015-05-01" @default.
• W2037648619 modified "2023-10-10" @default.
• W2037648619 title "Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry" @default.
• W2037648619 cites W1571473046 @default.
• W2037648619 cites W1594992171 @default.
• W2037648619 cites W1967657617 @default.
• W2037648619 cites W1985473671 @default.
• W2037648619 cites W1992974338 @default.
• W2037648619 cites W2000285638 @default.
• W2037648619 cites W2001763502 @default.
• W2037648619 cites W2015007634 @default.
• W2037648619 cites W2023481708 @default.
• W2037648619 cites W2054669275 @default.
• W2037648619 cites W2074769531 @default.
• W2037648619 cites W2078145079 @default.
• W2037648619 cites W2078251659 @default.
• W2037648619 cites W2120733999 @default.
• W2037648619 cites W2127451397 @default.
• W2037648619 cites W2157113624 @default.
• W2037648619 cites W2172216599 @default.
• W2037648619 cites W2331491942 @default.
• W2037648619 cites W4210961054 @default.
• W2037648619 doi "https://doi.org/10.1016/j.jhep.2014.10.044" @default.
• W2037648619 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25450208" @default.
• W2037648619 hasPublicationYear "2015" @default.
• W2037648619 type Work @default.
• W2037648619 sameAs 2037648619 @default.
• W2037648619 citedByCount "135" @default.
• W2037648619 countsByYear W20376486192014 @default.
• W2037648619 countsByYear W20376486192015 @default.
• W2037648619 countsByYear W20376486192016 @default.
• W2037648619 countsByYear W20376486192017 @default.
• W2037648619 countsByYear W20376486192018 @default.
• W2037648619 countsByYear W20376486192019 @default.
• W2037648619 countsByYear W20376486192020 @default.
• W2037648619 countsByYear W20376486192021 @default.
• W2037648619 countsByYear W20376486192022 @default.
• W2037648619 countsByYear W20376486192023 @default.
• W2037648619 crossrefType "journal-article" @default.
• W2037648619 hasAuthorship W2037648619A5003723462 @default.
• W2037648619 hasAuthorship W2037648619A5007464229 @default.
• W2037648619 hasAuthorship W2037648619A5008132779 @default.
• W2037648619 hasAuthorship W2037648619A5010739819 @default.
• W2037648619 hasAuthorship W2037648619A5019109535 @default.
• W2037648619 hasAuthorship W2037648619A5020337780 @default.
• W2037648619 hasAuthorship W2037648619A5022259822 @default.
• W2037648619 hasAuthorship W2037648619A5023275678 @default.
• W2037648619 hasAuthorship W2037648619A5035044684 @default.
• W2037648619 hasAuthorship W2037648619A5039624341 @default.
• W2037648619 hasAuthorship W2037648619A5046920680 @default.
• W2037648619 hasAuthorship W2037648619A5055304656 @default.
• W2037648619 hasAuthorship W2037648619A5057491763 @default.
• W2037648619 hasAuthorship W2037648619A5064179616 @default.
• W2037648619 hasAuthorship W2037648619A5072939769 @default.
• W2037648619 hasAuthorship W2037648619A5089993955 @default.
• W2037648619 hasBestOaLocation W20376486191 @default.
• W2037648619 hasConcept C126322002 @default.
• W2037648619 hasConcept C159047783 @default.
• W2037648619 hasConcept C197934379 @default.
• W2037648619 hasConcept C2522874641 @default.
• W2037648619 hasConcept C2776408679 @default.
• W2037648619 hasConcept C2776455275 @default.
• W2037648619 hasConcept C2777214474 @default.
• W2037648619 hasConcept C2778390639 @default.
• W2037648619 hasConcept C2780040827 @default.
• W2037648619 hasConcept C71924100 @default.
• W2037648619 hasConcept C90924648 @default.
• W2037648619 hasConceptScore W2037648619C126322002 @default.
• W2037648619 hasConceptScore W2037648619C159047783 @default.
• W2037648619 hasConceptScore W2037648619C197934379 @default.
• W2037648619 hasConceptScore W2037648619C2522874641 @default.
• W2037648619 hasConceptScore W2037648619C2776408679 @default.
• W2037648619 hasConceptScore W2037648619C2776455275 @default.
• W2037648619 hasConceptScore W2037648619C2777214474 @default.
• W2037648619 hasConceptScore W2037648619C2778390639 @default.
• W2037648619 hasConceptScore W2037648619C2780040827 @default.
• W2037648619 hasConceptScore W2037648619C71924100 @default.
• W2037648619 hasConceptScore W2037648619C90924648 @default.
• W2037648619 hasIssue "5" @default.
• W2037648619 hasLocation W20376486191 @default.

• next